Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Pulse Biosciences (PLSE) Stock Price & Analysis

292 Followers

PLSE Stock Chart & Stats

$53.29$0.22(0.41%)
At close: 4:00 PM EST
$40$45$50$55Aug 10Aug 24Sep 8Sep 21Oct 5Oct 19Nov 2
Day’s Range
$50.31 - $56.87
52-Week Range
$12.56 - $58.90
Previous Close
$53.07
Volume
N/A
Average Volume (3M)
407.26K
Market Cap
$3.92B
Enterprise Value
$3.41B
Total Cash (Recent Filing)
$189.19M
Total Debt (Recent Filing)
$6.36M
Price to Earnings (P/E)
―
Beta
1.09
Next Earnings
Apr 01, 2027 (Est.)
EPS Estimate
-0.31
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Proprietary Technology And IP

More than 285 owned patents and a decade of know-how can protect differentiation in nsPFA, while non-thermal lesion design targets consistent treatment with less collateral injury. This supports defensibility as clinical and commercial programs expand.

Clinical Efficacy Potential

Interim PRECISE-BTN results show 86% of 43 assessed patients achieved at least 50% volume reduction, with 72% median reduction, 78% quality-of-life improvement and no serious adverse events. These outcomes support broader thyroid adoption.

Funding And Balance-sheet Flexibility

$189.2M in cash and marketable securities and roughly two years of stated runway provide funding for pivotal studies, regulatory submissions and launch preparation. Low debt relative to equity adds flexibility while programs mature.

Bears Say

Heavy Cash Burn And Losses

TTM operating and free cash flow near negative $63M, alongside an $83.7M net loss, shows the platform is not self-funding. Persistent burn can require additional capital and may constrain investment choices even with the current cash cushion.

Limited Commercial Scale

Revenue is only about $1.5M TTM and gross profit about $0.14M, despite extensive clinical investment. This gap indicates commercial scale and unit economics remain unproven, leaving profitability dependent on successful adoption and future volume growth.

Delayed Milestones And Rising Spending

Final pivotal Nano-Pulse AF data are not expected until Q3 2027, with CE Mark and launch targeted for late 2027 and early 2028. Additional spending is expected to rise 15%-25%, extending the time and capital required to validate and commercialize.

Pulse Biosciences News

PLSE FAQ

What was Pulse Biosciences’s price range in the past 12 months?
Pulse Biosciences lowest stock price was $12.56 and its highest was $58.90 in the past 12 months.
What is Pulse Biosciences’s market cap?
Pulse Biosciences’s market cap is $3.92B.
When is Pulse Biosciences’s upcoming earnings report date?
Pulse Biosciences’s next earnings report is estimated for Apr 01, 2027 (not yet confirmed), which is in 142 days.
How were Pulse Biosciences’s earnings last quarter?
Pulse Biosciences released its earnings results on Nov 05, 2026. The company reported -$0.243 earnings per share for the quarter, beating the consensus estimate of -$0.31 by $0.067.
Is Pulse Biosciences overvalued?
According to Wall Street analysts Pulse Biosciences’s price is currently Undervalued.
Does Pulse Biosciences pay dividends?
Pulse Biosciences does not currently pay dividends.
What is Pulse Biosciences’s EPS estimate?
Pulse Biosciences’s EPS estimate is -0.31.
How many shares outstanding does Pulse Biosciences have?
Pulse Biosciences has 73,548,930 shares outstanding.
What happened to Pulse Biosciences’s price movement after its last earnings report?
Pulse Biosciences reported an EPS of -$0.243 in its last earnings report, beating expectations of -$0.31. Following the earnings report the stock price went up 0.415%.
Which hedge fund is a major shareholder of Pulse Biosciences?
Hedge funds hold Pulse Biosciences shares: the largest hedge-fund position in Pulse Biosciences is 71,886,256 shares, and hedge funds increased their holdings by 114.7K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology